Article Details

Novartis Bolsters Inflammation Pipeline with Up-to-$1.6B Acquisition of IFM Subsidiary

Retrieved on: 2019-03-31 22:26:15

Tags for this article:

Click the tags to see associated articles and topics

Novartis Bolsters Inflammation Pipeline with Up-to-$1.6B Acquisition of IFM Subsidiary. View article details on hiswai:

Excerpt

<div>Participants in the financing included management of parent company IFM, <b>Atlas</b> <b>Venture</b>, Abingworth—and Bristol-Myers Squibb (BMS), which in ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up